Skip to main content Accessibility help

Cannabis in the Treatment of Traumatic Brain Injury: A Primer for Clinicians

  • Karl Grenier (a1), Fallon Ponnambalam (a1), David Lee (a1), Rebecca Lauwers (a1) and Shree Bhalerao (a1)...


Our clinical experience at a specialized brain injury clinic suggests that numerous patients with traumatic brain injury (TBI) are using cannabis to alleviate their symptoms. While this patient population often inquires about the evidence of using cannabis post-head injury for the neurosensory, neurocognitive, and neuropsychiatric sequelae, most health professionals have little to no knowledge of this evidence. Given the recent legalization of recreational cannabis in Canada, questions and guidance related to cannabis use following a TBI are likely to become more common. This article reviews the evidence for cannabis use in psychiatric disorders with or without TBI. Overall, we found that the evidence for the use of cannabis among TBI patients is sparse and that patients tend to have little knowledge of the proven benefits and diverse effects of cannabis use. We feel this paper can serve as a stepping stone for future studies that explore the impact of cannabis use in a TBI population and can guide clinicians in advising their patients.

Cannabis et traitement des traumatismes cranio-cérébraux: les prémices de son utilisation par les médecins cliniciens. Notre expérience clinique au sein d’un établissement spécialisé dans les traumatismes cranio-cérébraux (TCC) nous incline à penser que de nombreux patients victimes de tels traumatismes consomment du cannabis pour soulager leurs symptômes. Bien que ces patients tentent fréquemment de s’informer quant aux bienfaits du cannabis, notamment en ce qui concerne leurs séquelles neurosensorielles, neurocognitives et neuropsychiatriques, la plupart des professionnels de la santé n’ont que peu, voire aucune connaissance, à ce sujet. Compte tenu de la récente légalisation de la consommation récréative du cannabis au Canada, il est à prévoir que des questions et des conseils en lien avec l’utilisation du cannabis à la suite d’un TCC vont devenir monnaie courante. Cet article entend passer en revue les preuves liant le cannabis au soulagement de troubles psychiatriques, et ce, que des patients aient été victimes ou non de TCC. De façon générale, nous avons constaté que les preuves de l’utilisation du cannabis par des patients victimes de TCC sont rares. Nous avons aussi noté que ces patients ont tendance à avoir des connaissances limitées quant aux bénéfices avérés et aux divers effets du cannabis. Bref, nous sommes d’avis que cet article pourrait servir de tremplin à l’élaboration d’études dont le but serait d’explorer les conséquences de l’utilisation du cannabis chez des patients ayant été victimes de TCC. Nous croyons aussi que cet article pourrait permettre aux médecins cliniciens de mieux guider leurs patients.


Corresponding author

Correspondence to: Shree Bhalerao, Department of Psychiatry, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada. Email:


Hide All
1. Nguyen, R, Fiest, KM, McChesney, J, et al. The international incidence of traumatic brain injury: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(6):774–85.
2. Rusnak, M. Traumatic brain injury: giving voice to a silent epidemic. Nat Rev Neurol. 2013;9(4):186–7.
3. Selassie, AW, Zaloshnja, E, Langlois, JA, Miller, T, Jones, P, Steiner, C. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J Head Trauma Rehabil. 2008;23(2):123–31.
4. Osier, ND, Dixon, CE. Catecholaminergic based therapies for functional recovery after TBI. Brain Res. 2016;1640(Pt A):1535.
5. Yue, JK, Burke, JF, Upadhyayula, PS, et al. Selective serotonin reuptake inhibitors for treating neurocognitive and neuropsychiatric disorders following traumatic brain injury: an evaluation of current evidence. Brain Sci. 2017;7(12):126.
6. Chen, YH, Huang, EY, Kuo, TT, Miller, J, Chiang, YH, Hoffer, BJ. Impact of traumatic brain injury on dopaminergic transmission. Cell Transplant. 2017;26(7):1156–68.
7. Shin, SS, Dixon, CE. Alterations in cholinergic pathways and therapeutic strategies targeting cholinergic system after traumatic brain injury. J Neurotrauma. 2015;32(19):1429–40.
8. Abe, K, Shimada, R, Okada, Y, Kibayashi, K. Traumatic brain injury decreases serotonin transporter expression in the rat cerebrum. Neurol Res. 2016;38(4):358–63.
9. Kosari-Nasab, M, Shokouhi, G, Azarfarin, M, BannazadehAmirkhiz, M, Mesgari Abbasi, M, Salari, A-A. Serotonin 5-HT1A receptors modulate depression-related symptoms following mild traumatic brain injury in male adult mice. Metab Brain Dis. 2019;34(2):575–82.
10. Saija, A, Hayes, RL, Lyeth, BG, Edward Dixon, C, Yamamoto, T, Robinson, SE. The effect of concussive head injury on central cholinergic neurons. Brain Res. 1988;452(1–2):303–11.
11. Massucci, JL, Kline, AE, Ma, X, Zafonte, RD, Dixon, CE. Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett. 2004;372(1–2):127–31.
12. Huger, F, Patrick, G. Effect of concussive head injury on central catecholamine levels and synthesis rates in rat brain regions. J Neurochem. 1979;33(1):8995.
13. Dunn-Meynell, AA, Hassanain, M, Levin, BE. Norepinephrine and traumatic brain injury: a possible role in post-traumatic edema. Brain Res. 1998;800(2):245–52.
14. Iverson, GL, Keene, CD, Perry, G, Castellani, RJ. The need to separate chronic traumatic encephalopathy neuropathology from clinical features. J Alzheimer’s Dis. 2018;61(1):1728.
15. Schwab, N, Hazrati, LN. Assessing the limitations and biases in the current understanding of chronic traumatic encephalopathy. J Alzheimer’s Dis. 2018;64(4):1067–76.
16. McKee, AC, Cairns, NJ, Dickson, DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):7586.
17. Neurobehavioral Guidelines Working G, Warden, DL, Gordon, B, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurochem. 2006;23(10):1468–501.
18. Park, E, Bell, JD, Baker, AJ. Traumatic brain injury: can the consequences be stopped? CMAJ. 2008;178(9):1163–70.
19. Broshek, DK, De Marco, AP, Freeman, JR. A review of post-concussion syndrome and psychological factors associated with concussion. Brain Inj. 2015;29(2):228–37.
20. Blennow, K, Brody, DL, Kochanek, PM, et al. Traumatic brain injuries. Nat Rev Dis Primers. 2016;2:16084.
21. Simon, DW, McGeachy, MJ, Bayir, H, Clark, RSB, Loane, DJ, Kochanek, PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13(9):572.
22. Kokiko-Cochran, ON, Godbout, JP. The inflammatory continuum of traumatic brain injury and Alzheimer’s disease. Front Immunol. 2018;9:672.
23. Reus, GZ, Fries, GR, Stertz, L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015;300:141–54.
24. Hong, H, Kim, BS, Im, HI. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J. 2016;20(Suppl 1):S27.
25. Bergold, PJ. Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol. 2016;275 (Pt 3):367–80.
26. Zurier, RB, Burstein, SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016;30(11):3682–89.
27. Katz, PS, Sulzer, JK, Impastato, RA, Teng, SX, Rogers, EK, Molina, PE. Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma. 2015;32(5):297306.
28. De Guzman, E, Ament, A. Neurobehavioral management of traumatic brain injury in the critical care setting: an update. Crit Care Clin. 2017;33(3):423–40.
29. Abou El Fadl, MH, O’Phelan, KH. Management of traumatic brain injury: an update. Neurosurg Clin North Am. 2018;29(2):213–21.
30. Devane, WA, Hanus, L, Breuer, A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946–49.
31. Reggio, PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17(14):1468–86.
32. Herkenham, M, Lynn, AB, Johnson, MR, Melvin, LS, de Costa, BR, Rice, KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11(2):563–83.
33. Schurman, LD, Lichtman, AH. Endocannabinoids: a promising impact for traumatic brain injury. Front Pharmacol. 2017;8:69.
34. Mechoulam, R, Panikashvili, D, Shohami, E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8(2):5861.
35. Shohami, E, Gallily, R, Mechoulam, R, Bass, R, Ben-Hur, T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol. 1997;72(2):169–77.
36. Turna, J, Patterson, B, Van Ameringen, M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006–17.
37. Degenhardt, L, Hall, W. Cannabis and psychosis. Curr Psychiatry Rep. 2002;4(3):191–96.
38. Andreasson, S, Allebeck, P, Rydberg, U. Schizophrenia in users and nonusers of cannabis. a longitudinal study in Stockholm County. Acta Psychiatr Scand. 1989;79(5):505–10.
39. Hamilton, I. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addict. 2017;112(9):1653–57.
40. Arseneault, L, Cannon, M, Poulton, R, Murray, R, Caspi, A, Moffitt, TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–13.
41. Di Forti, M, Sallis, H, Allegri, F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.
42. Zammit, S, Allebeck, P, Andreasson, S, Lundberg, I, Lewis, G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.
43. Marconi, A, Di Forti, M, Lewis, CM, Murray, RM, Vassos, E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–69.
44. Gibbs, M, Winsper, C, Marwaha, S, Gilbert, E, Broome, M, Singh, SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:3947.
45. Lev-Ran, S, Roerecke, M, Le Foll, B, George, TP, McKenzie, K, Rehm, J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol. Med. 2014;44(4):797810.
46. Gruber, AJ, Pope, HG , Jr., Brown, ME. Do patients use marijuana as an antidepressant? Depression. 1996;4(2):7780.
47. Karniol, IG, Shirakawa, I, Kasinski, N, Pfeferman, A, Carlini, EA. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol [Internet]. 1974;28(1):172–77.
48. Hser, YI, Mooney, LJ, Huang, D, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017;81:5358.
49. Ablon, SL, Goodwin, FK. High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry. 1974;131(4):448–53.
50. Zuardi, A, Shirakawa, I, Finkelfarb, E, Karniol, IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacol. 1982;76:245–50.
51. Greer, GR, Grob, CS, Halberstadt, AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoact Drugs. 2014;46(1):7377.
52. Mizrachi Zer-Aviv, T, Segev, A, Akirav, I. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. Behav Pharmacol. 2016;27(7):561–69.
53. O’Neil, ME, Nugent, SM, Morasco, BJ, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Internal Med. 2017;167(5):332–40.
54. Steenkamp, MM, Blessing, EM, Galatzer-Levy, IR, Hollahan, LC, Anderson, WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207–16.
55. Medical Association C. Government of Canada-task force on Marijuana legalization and regulation CMA submission [Internet]. 2016.
56. Fontes, MA, Bolla, KI, Cunha, PJ et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–47.
57. Volkow, ND, Baler, RD, Compton, WM, Weiss, SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27.
58. Anstey, KJ, Butterworth, P, Jorm, AF, Christensen, H, Rodgers, B, Windsor, TD. A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms. J Clin Epidemiol. 2004;57(11):1202–09.
59. Jorge, RE, Robinson, RG, Moser, D, Tateno, A, Crespo-Facorro, B, Arndt, S. Major depression following traumatic brain injury. Arch Gen Psychiatry. 2004;61(1):4250.
60. Guskiewicz, KM, Mihalik, JP, Shankar, V, et al. Measurement of head impacts in collegiate football players: relationship between head impact biomechanics and acute clinical outcome after concussion. Neurosurgery. 2007;61(6):1244–52; discussion 52-3.
61. Silver, JM, McAllister, TW, Arciniegas, DB. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiatry. 2009;166(6):653–61.
62. Koponen, S, Taiminen, T, Portin, R, et al. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry. 2002;159(8):1315–21.
63. Kennedy, E, Heron, J, Munafo, M. Substance use, criminal behaviour and psychiatric symptoms following childhood traumatic brain injury: findings from the ALSPAC cohort. Eur Child Adolesc Psychiatry. 2017;26(10):1197–206.
64. Walker, R, Cole, JE, Logan, TK, Corrigan, JD. Screening substance abuse treatment clients for traumatic brain injury: prevalence and characteristics. J Head Trauma Rehabil. 2007;22(6):360–67.
65. Allen, S, Stewart, SH, Cusimano, M, Asbridge, M. Examining the relationship between traumatic brain injury and substance use outcomes in the Canadian population. Subst Use Misuse. 2016;51(12):1577–86.
66. Ilie, G, Adlaf, EM, Mann, RE, Ialomiteanu, A, Hamilton, H, Rehm, J, et al. Associations between a history of traumatic brain injuries and current cigarette smoking, substance use, and elevated psychological distress in a population sample of Canadian adults. J Neurotrauma. 2015;32(14):1130–34.
67. Ilie, G, Mann, RE, Hamilton, H, et al. Substance use and related harms among adolescents with and without traumatic brain injury. J Head Trauma Rehabil. 2015;30(5):293301.
68. Cicerone, K, Levin, H, Malec, J, Stuss, D, Whyte, J. Cognitive rehabilitation interventions for executive function: moving from bench to bedside in patients with traumatic brain injury. J CognNeurosci. 2006;18(7):1212–22.
69. Payne, HC. Traumatic brain injury, depression and cannabis use – assessing their effects on a cognitive performance. Brain Inj. 2000;14(5):479–89.
70. Rabner, J, Gottlieb, S, Lazdowsky, L, LeBel, A. Psychosis following traumatic brain injury and cannabis use in late adolescence. Am J Addict. 2016;25(2):91–3.
71. Soler, JM, Muller, HA, Trautlein, JJ, Donovan, JW. Posttraumatic aneurysms of the hand. JACEP. 1979;8(6):232–34.
72. Jain, SS, A.S. Frontal lobe abnormality and psychosis in traumatic brain injury and cannabis use. ASEAN J Psychiatry. 2017;18(1):9598.
73. Wilson, JR. Blast-traumatic brain injury (TBI) with post-traumatic stress disorder (PTSD): a treatable condition? Psychol Cogn Sci Open J. 2017;3(4):1922.
74. Hunt, C, Guo, M, Michalak, A, et al. Can early life experiences affect cannabis use following a concussion? A survey of patients attending a tertiary care clinic. Poster session presented at International Brain Association, 13th World Congress on Brian Injury. Toronto, ON: St. Michael’s Hospital Head Injury Clinic, University of Toronto; 2019 March 13–16.
75. Brandt, A, Rehm, J, Lev-Ran, S. Clinical correlates of cannabis use among individuals with attention deficit hyperactivity disorder. J NervMent Dis. 2018;206(9):726–32.
76. Fergusson, DM, Boden, JM. Cannabis use and adult ADHD symptoms. Drug Alcohol Depend. 2008;95(1–2):9096.
77. Nugent, SM, Morasco, BJ, O’Neil, ME, et al. The effects of Cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Internal Med. 2017;167(5):319–31.
78. Deshpande, A, Mailis-Gagnon, A, Zoheiry, N, Lakha, SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Physician. 2015;61(8):e37281.
79. Mucke, M, Phillips, T, Radbruch, L, Petzke, F, Hauser, W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182.


Related content

Powered by UNSILO

Cannabis in the Treatment of Traumatic Brain Injury: A Primer for Clinicians

  • Karl Grenier (a1), Fallon Ponnambalam (a1), David Lee (a1), Rebecca Lauwers (a1) and Shree Bhalerao (a1)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.